Clinical Features Reflect Exon Sites of EGFR Mutations in Patients with Resected Non-Small-Cell Lung Cancer.
10.3346/jkms.2007.22.3.393
- Author:
Im Il NA
1
;
Jin Kyung RHO
;
Yun Jung CHOI
;
Cheol Hyeon KIM
;
Jae Soo KOH
;
Baek Yeol RYOO
;
Sung Hyun YANG
;
Jae Cheol LEE
Author Information
1. Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological & Medical Sciences, Seoul, Korea. jclee@kcch.re.kr
- Publication Type:Original Article
- Keywords:
Carcinoma, Non-small-cell Lung;
Receptor, Epidermal Growth Factor;
Genes, Ras;
Mutation
- MeSH:
Adult;
Aged;
Aged, 80 and over;
Carcinoma, Non-Small-Cell Lung/diagnosis/*genetics/*surgery;
Disease-Free Survival;
*Exons;
Female;
Humans;
Lung Neoplasms/diagnosis/*genetics/*surgery;
Male;
Middle Aged;
*Mutation;
Proto-Oncogene Proteins p21(ras)/genetics;
Receptor, Epidermal Growth Factor/*genetics;
Sex Factors;
Treatment Outcome
- From:Journal of Korean Medical Science
2007;22(3):393-399
- CountryRepublic of Korea
- Language:English
-
Abstract:
The aim of the current study was to determine the clinical significance according to the subtypes of epidermal growth factor receptor (EGFR) mutations and presence of KRAS mutations in operable non-small-cell lung cancer (NSCLC). We sequenced exons 18-21 of the EGFR tyrosine kinase domain and examined mutations in codons 12 and 13 of KRAS in tissues of patients with NSCLC who had undergone surgical resection. EGFR mutations were more frequent in never-smokers than smokers (33% vs. 14%, respectively; p=0.009) and in females than in males (31% vs. 16%, respectively; p=0.036). Mutations in exon 18-19 and 20-21 were found in 10 and 22 patients, respectively. Never-smokers and broncho-alveolar cell carcinoma features were positively associated with a mutation in exon 18-19 (p=0.027 and 0.016, respectively). The five-year survival rate in patients with a mutation in exons 18-19 (100%) was higher than that in patients without such mutation (47%; p=0.021). KRAS mutations were found in 16 patients (12%) and were not related to the overall survival (p=0.742). Patients with an EGFR mutation in exons 18-19 had better survival than patients without such mutation. Subtypes of EGFR mutations may be prognostic factors in patients undergoing curative resection.
